Castle Biosciences Data Suggests Gene Test Can Reduce Unnecessary Melanoma Biopsies
Event summary
- Castle Biosciences will present data at SSO 2026 showing DecisionDx-Melanoma’s i31-SLNB test can identify low-risk T1b–T2a melanoma patients who may safely avoid sentinel lymph node biopsy (SLNB).
- The test integrates a 31-gene expression profile with clinicopathologic factors for personalized risk assessment.
- DecisionDx-Melanoma has been clinically validated in over 10,000 patient samples and ordered more than 220,000 times since launch.
- The presentation is part of the SSO 2026 Annual Meeting, held March 5-7 in Phoenix.
The big picture
Castle Biosciences’ presentation at SSO 2026 underscores the growing role of molecular diagnostics in precision oncology. The data suggests that gene expression profiling could reduce unnecessary surgical procedures for melanoma patients, aligning with broader trends toward personalized medicine. The test’s integration of tumor biology with clinical factors may set a new standard for risk stratification in early-stage melanoma, potentially expanding its use in clinical guidelines and reimbursement policies.
What we're watching
- Clinical Adoption
- Whether the data will accelerate physician adoption of DecisionDx-Melanoma for SLNB decision-making.
- Regulatory Alignment
- How the test’s alignment with National Comprehensive Cancer Network® guidelines may influence payer coverage.
- Competitive Positioning
- The pace at which Castle Biosciences can differentiate its test in the growing market for molecular diagnostics in oncology.
Related topics